EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer – A nationwide cohort study

Tone Bjørge iD, Vidar Hjellvik, Line Bjørge, Isabel Dos-Santos-Silva, Kari Furu, Rune Kvåle, Anders Engeland iD

BJOG: An International Journal of Obstetrics & Gynaecology · 2023

DOI: 10.1111/1471-0528.17410 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2023. Verfasst von Tone Bjørge und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Uterine Neoplasms, Ovarian Neoplasms, Genital Neoplasms, Female. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Norwegian Cancer Society, Kreftforeningen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate both incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer.

Design

A prospective study.

Setting

Population‐based registries. Population 1.76 million women, including 17 500 women with gynaecological cancers.

Methods

Data from the Cancer Registry of Norway was linked to the Norwegian Prescription Database and other national databases. Main Outcome Measures Prevalence ratios (PRs) and hazard ratios (HRs), with 95% confidence intervals (CIs), of dispensed drugs in gynaecological cancer patients (up to 15 years after diagnosis) were estimated by log‐binomial and Cox regression, respectively, with cancer‐free women as reference.

Results

For gynaecological cancer patients, the incidence of drugs used for pain control was higher than in cancer‐free women, especially the first 5 years after diagnosis, and the prevalence was high at least 10 years after. The prevalence of sex hormones was high in women with gynaecological cancer at least 10 years after diagnosis (cervical and ovarian cancer PR = 23, 95% CI 18–30 and PR = 24, 95% CI 15–38, respectively), but low in cancer‐free women (0.3%). Patients with uterine corpus cancer had a higher prevalence of antidiabetics before and at least 10 years after diagnosis, most pronounced in women diagnosed before age 50 (PR = 10, 95% CI 5.0–21). The prevalence of antidepressants was moderately elevated in women with gynaecological cancers.

Conclusions

Gynaecological cancer survivors, particularly cervical and ovarian cancer survivors, had an increased long‐term use of drugs for pain control and sex hormones. Survivors of uterine corpus cancer used antidiabetics more often, both before and after diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine NeoplasmsOvarian NeoplasmsGenital Neoplasms, FemaleAdultHumansFemaleMiddle AgedCohort StudiesIncidencePrevalenceProspective StudiesSurvivorsChronic DiseasePain

Stichwörter der Autor:innen

cervical cancerchronic diseasesdrugsmedicationovarian cancerpharmacoepidemiologypopulation-baseduterine corpus cancer

Autor:innen und Institutionen

  • Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • Cancer Registry of Norway, Oslo, Norway.
  • Norwegian Institute of Public Health, Bergen/Oslo, Norway.
  • Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
  • Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.

ORCID-Profile: Tone Bjørge, Anders Engeland

Förderung

  • Norwegian Cancer Society
  • Kreftforeningen

Zitieren

APA

Bjørge, T., Hjellvik, V., Bjørge, L., Dos-Santos-Silva, I., Furu, K., Kvåle, R., & Engeland, A. (2023). Incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer – A nationwide cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17410

Vancouver

Bjørge T, Hjellvik V, Bjørge L, Dos-Santos-Silva I, Furu K, Kvåle R, et al. Incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer – A nationwide cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2023. doi:10.1111/1471-0528.17410

BibTeX
@article{Bjrge2023,
  author = {Bjørge, Tone and Hjellvik, Vidar and Bjørge, Line and Dos-Santos-Silva, Isabel and Furu, Kari and Kvåle, Rune and Engeland, Anders},
  title = {Incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer – A nationwide cohort study},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2023},
  doi = {10.1111/1471-0528.17410}
}
Kostenlos starten →